Cargando…
A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer
Background: Cancer is a major health problem worldwide and the leading cause of death in many countries. Preclinical studies have shown the therapeutic anticancer effects of SH003, a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii. The present st...
Autores principales: | Cheon, Chunhoo, Ko, Seong-Gyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081467/ https://www.ncbi.nlm.nih.gov/pubmed/32186413 http://dx.doi.org/10.1177/1534735420911442 |
Ejemplares similares
-
Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol
por: Cheon, Chunhoo, et al.
Publicado: (2020) -
Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol
por: Cheon, Chunhoo, et al.
Publicado: (2018) -
SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells
por: Kim, Tae Woo, et al.
Publicado: (2020) -
State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent
por: Lee, Kangwook, et al.
Publicado: (2022) -
SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells
por: Seo, Hye-Sook, et al.
Publicado: (2017)